High affinity immunoglobulin epsilon receptor subunit beta (MS4A2) mRNA (MS4A2 mRNA)

MS4A2 (Membrane Spanning 4-Domains A2) encodes the beta subunit of the high-affinity IgE receptor (FcεRI), which is primarily expressed on mast cells and basophils (UniProt P30273). This subunit acts as a signaling amplifier, significantly increasing the sensitivity and magnitude of the cellular response to IgE-bound allergens (PubMed: 15546383). Genetic variations in the MS4A2 gene have been strongly linked to atopy and bronchial asthma, making it a key focus for respiratory and dermatological research (NCBI Gene: 2206). Targeting the MS4A2 mRNA using RNA interference (RNAi) or antisense oligonucleotides (ASOs) represents a precision medicine approach to downregulate the receptor's expression and inhibit the release of pro-inflammatory mediators (PubMed: 22403345). By reducing the availability of the beta subunit, these therapies aim to decrease the surface density of FcεRI and dampen the allergic cascade without broad immunosuppression. This strategy is particularly relevant for patients with severe allergic conditions who are refractory to standard treatments like corticosteroids or anti-IgE biologics (PubMed: 10449214).

Other names

Fc epsilon RI beta mRNAFCERB mRNAFcERI beta mRNAMembrane-spanning 4-domains subfamily A member 2 mRNAAtopyAPY

RNA interference (RNAi) or antisense knockdown of MS4A2 mRNA to prevent the translation of the FcεRI beta subunit, which destabilizes the high-affinity IgE receptor complex and reduces mast cell sensitivity to allergens.